Table 3 Ongoing or recently completed clinical trials involving molecules that target apoptosis

ABT-263

(in combination with erlotinib or irinotecan)

Abbott

Bcl-2 family of proteins

Solid tumours

Phase I

ABT-263

(in combination with docetaxel)

Abbott

Bcl-2 family of proteins

Solid tumours

Phase I

ABT-263

(in combination with paclitaxel)

Abbott

Bcl-2 family of proteins

Chronic lymphocytic leukaemia

Phase I

ABT-263

Genentech

Bcl-2 family of proteins

Chronic lymphocytic leukaemia

Phase II

AT-101

(Gossypol)

Roswell Park Cancer Institute

Bcl-2 family of proteins

Lymphocytic leukaemia,

chronic B-cell leukaemia

Phase I

Phase II

AT-406

Ascenta Therapeutics

IAPs

Solid tumours,

lymphoma

Phase I

AT-406

Ascenta Therapeutics

IAPs

Acute myelogenous leukaemia

Phase I

ENZ-3042

Therapeutic Advances in Childhood Leukaemia Consortium

IAPs

Acute, childhood and T cell lymphoblastic leukaemia

Phase I

GX15-070MS

(Obotoclax)

Children's Oncology Group

Bcl-2 family of proteins

Leukaemia,

lymphoma

unspecified childhood solid tumour

Phase I

GX15-070MS

(Obotoclax)

Arthur G. James Cancer Hospital & Richard J. Solove Research Institute

Bcl-2 family of proteins

Lymphoma

Phase I

Phase II

HGS-1029

Human Genome Sciences

IAPs

Advanced solid tumours

Phase I

HGS-1029

Human Genome Sciences

IAPs

Advanced solid tumours

Phase I

LCL-161

Novartis Pharmaceuticals

IAPs

Solid tumours

Phase I

RO5458640

Hoffmann-La Roche

TNF-like weak inducer of apoptosis (TWEAK) ligand

Advanced solid tumours

Phase I